| Skin Cancer |
1 |
0.99 |
| Lung Cancer |
0 |
0.81 |
| Toxicology |
0 |
0.66 |
| Breast Cancer |
0 |
0.64 |
| Cancer |
0 |
0.59 |
| Id Reaction |
0 |
0.59 |
| Dermatitis |
0 |
0.58 |
| Squamous Cell Carcinoma |
0 |
0.47 |
| Non-Small Cell Lung Cancer |
0 |
0.46 |
| Small Cell Lung Cancer (SCLC) |
0 |
0.44 |
| Food and Drug Administration (FDA) |
0 |
0.42 |
| Triple Negative Breast Cancer |
0 |
0.34 |
| Non-Hodgkin Lymphoma (NHL) |
0 |
0.27 |
| Stem Cell Research and Therapy |
0 |
0.25 |
| B-Cell Lymphoma |
0 |
0.18 |
| Hodgkin Lymphoma |
0 |
0.18 |
| Organ Transplantation |
0 |
0.18 |
| Lung |
0 |
0.17 |
| Lymphoma |
0 |
0.17 |
| Melanoma |
0 |
0.17 |
| Surgery |
0 |
0.17 |
| Transplantation |
0 |
0.17 |
| Graft Rejection |
0 |
0.12 |
| Microsatellite Instability-High |
0 |
0.12 |
| Breast |
0 |
0.08 |
| Cervical Region |
0 |
0.08 |
| Colitis |
0 |
0.08 |
| Corticosteroids |
0 |
0.08 |
| Esophagus |
0 |
0.08 |
| Hepatitis |
0 |
0.08 |
| Hepatitis A |
0 |
0.08 |
| Inflammatory Bowel Disease |
0 |
0.08 |
| Intravenous |
0 |
0.08 |
| Microsatellite Instability |
0 |
0.08 |
| Nephritis |
0 |
0.08 |
| Tissue |
0 |
0.08 |
| Tumor |
0 |
0.08 |